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1. Introduction
Systemic lupus erythematosus, or SLE is a multisystem autoimmune disease that occurs
predominantly in African American women of childbearing age, who generally have more
severe disease. There are several multi-ethnic global lupus registries ongoing to collect better
information on the epidemiology of SLE worldwide [1]. The annual incidence of SLE is 3 cases /
100,000 with prevalence rates reported up to 144/100,000 among the general population [1-2],
90% of SLE patients being female gender. African Americans and Hispanics as well as males
with lupus, general ly have more severe diseases, particularly renal disease, with some studies
also showing this association in Asians [1-2]. SLE is a thrombophilic state. Patients with SLE-
related hypercoagulability can develop arterial and venous thrombosis as well as intrauterine
fetal demise, such as miscarriages and stillbirths. Multiple mechanisms contribute to hyper‐
coagulability in SLE, including lupus specific factors such as antiphospholipid antibodies.
These antibodies also contribute to cardiovascular and cerebrovascular disease in lupus. The
inflammation in SLE can increase certain procoagulant factors which can tip the balance
towards thrombosis. In addition, platelet hyperfunction in SLE promotes thrombogenesis and
is particularly important in premature cardiovascular disease management in women with
lupus. Thrombogenesis in SLE is best explained by the multiple-hit theory in which several
procoagulant or anticoagulant effects occur, which additively can attain the critical overall
effect needed to generate a blood clot. Thus, when assessing lupus patients for thrombosis or
intrauterine fetal demise, a larger laboratory work up is needed to define the coagulation
abnormalities in order to fine tune the most effective anticoagulation regimen as well as
determine length of treatment. This chapter will briefly review the clinical syndromes
associated with thrombophilic lupus related antibodies, with an emphasis on pregnancy loss,
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cardiovascular disease and clotting, the multiple mechanisms for hypercoagulability in SLE,
and discuss the complexity of this problem in this population.
2. Epidemiology
2.1. Vascular thrombosis
The epidemiology of vascular thrombosis is well described in SLE and with several studies
showing an increased risk for arterial and venous thrombosis. Arterial and venous thrombosis
occurs in approximately 10% of SLE patients [3-7] with thrombosis being a major cause of death
in patients with lupus [8]. Gender differences have been reported with male SLE patients
having a higher prevalence of thrombosis and antiphospholipid antibody syndrome compared
to women with lupus [9]. Thrombovascular events occur throughout the course of lupus
disease with an increase risk over time [10-11]. Arterial vascular events occur more frequently
in post- menopausal women with lupus and are associated with age, disease duration, smoking
and mean dose of glucocorticoids [12]. Venous thrombosis is also associated with smoking in
lupus [12]. Other risk factors for thrombosis in lupus include high disease activity, lupus
nephritis /nephrotic syndrome, elevated homocysteine, and the presence of antiphospholipid
antibodies [11, 13-16].
2.2. Pregnancy loss
The factors which increase thrombosis risk also promote pregnancy loss in lupus. Patients with
SLE have increased frequencies of intrauterine growth restriction and fetal demise (miscarriage
and stillbirth) which can predate the diagnosis of lupus [17-18]. Pregnancy complications in
SLE are fairly common with maternal hypertensive complications occurring in 10-20%,
preterm births in 20% and fetal growth restriction occurring in about 28%, with an average
drop in fetal growth weight to be 16% [18-19]. Fetal wastage is markedly increased in SLE with
stillbirths occurring in 4-22% and miscarriage rates reported to range from approximately
10-46% [18-19]. The increased stillbirth rate in SLE is 4 fold greater than the general population
[18]. Intrauterine demise and adverse fetal outcome in SLE are related in great part to lupus
specific thrombophilic factors, which can cause placental infarctions, decidual vasculopathy,
and lower placental weight [20-22]. Placental histopathological findings in SLE patients with
lupus anticoagulant or anti-cardiolipin antibodies include extensive infarctions due to
decidual vasculopathy (related to fibrinoid necrosis in the wall of decidual arterioles and
thrombosis), syncytial knots, and perivillous fibrinoid change [20-22]. In addition, there is a
decrease in vasculo-syncytial membranes,an increase in fibrosis and an increase in hypovas‐
cular villi all which can lead to fetal growth restriction or demise [20-22]. Pregnancy itself is a
hypercoagulable state with fetal demise, thrombosis and pre-eclampsia being related to Factor
V Leiden mutation, prothrombin gene mutation 20210A, and deficiencies of anti-thrombin III,
protein C and protein S [23]. Thus, SLE specific thrombophilic factors are additive to the
background of pregnancy related hypercoagulability (multiple hits), and this increases the
occurrence of adverse fetal outcomes in lupus.
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2.3. Premature cardiovascular disease
Lupus-specific thrombophilic factors contribute to premature cardiac disease and atheroscle‐
rosis in this population. These lupus specific factors can affect the endothelium resulting in
premature arterial vascular disease contributing to the accelerated/premature atherosclerosis
observed in SLE [24]. Atheroma formation is initiated when oxidized low density lipoprotein
(LDL) is taken up by foam cells in vascular endothelium [24-25]. High density lipoprotein
(HDL) and Apo-A1 are protective factors against atherosclerosis. β-2 glycoprotein-1 binding
to oxidized LDL facilitates uptake by foam cells [26]. Patients with SLE have antibodies to LDL/
β-2 glycoprotein-1 complexes, HDL, and Apo –A1 [26-27]. Antibodies to HDL and Apo A-1
cross react with cardiolipin and prevent HDL and Apo-1 protection against atherosclerosis.
Antibodies to oxidized LDL may cross react with β-2 glycoprotein-1 and may enhance uptake,
thus promoting plaque formation [25-28]. Anticardiolipin antibody binding exposes immu‐
nogenic and normally hidden (or cryptic) epitopes on β-2 glycoprotein-1, which can bind to
anti- β-2 glycoprotein-1 antibodies. These antibodies bind to adhered β-2 glycoprotein-1 on
endothelial cells which causes endothelial activation and subsequent up regulation of inflam‐
matory and procoagulant factors [24-26]. In addition, adhered β-2 glycoprotein-1 on oxidized
LDL promotes LDL uptake by macrophages, thus facilitating plaque formation [24-26, 28].
During the acute phase response, HDL can be converted to pro-inflammatory molecules which
promote LDL oxidation. Chronic inflammation can cause HDL dysfunction in SLE. HDL has
been found to be pro-inflammatory in women with SLE and is termed pro-inflammatory HDL
or piHDL [25-26, 28]. More than 85% patients with SLE and carotid plaques had piHDL vs.
40% in those without plaques [27]. Pro- inflammatory HDL is an independent risk factor for
atherosclerosis in rheumatoid arthritis and antiphospholipid antibody syndrome [26, 28]. The
prevalence of moderate to severe atherosclerosis in SLE at autopsy is 52% [29]. There is a higher
prevalence of coronary artery disease in SLE than general population which is not predicted
by traditional risk factors or increase in lupus activity alone [30-39]. Mortality studies show
coronary artery disease (CAD) /myocardial infarction (MI) is a frequent cause of death in SLE
and occurs in 11-48% of SLE patients [3, 30-35]. Death from CAD in SLE is disproportionately
larger in late disease, with CAD/MI being the leading cause of death in SLE survivors. This
accounts for the late peak in mortality in SLE [36-38]. Although there are a greater number of
CAD risk factors (hypertension, diabetes mellitus, dyslipidemia, sedentary life style) in SLE
patients than matched controls, the increased atherosclerosis in SLE is not fully attributed to
these traditional risk factors [39-41]. Several other studies have reported an increased risk of
cardiovascular disease in SLE. After controlling for age, sex, cholesterol, hypertension, diabetes
mellitus, tobacco use the relative risk was 10.1 for non-fatal myocardial infarction [95%, CI
5.8-15.6] and 17.0 for death due to coronary artery disease (CI 8.1-29.7) [42]. Esdaile also
reported a 7.5X increased risk for developing coronary artery disease in SLE [42]. Progression
of coronary artery calcification has been associated with age, cholesterol and smoking [43]. In
particular, premenopausal aged women with lupus seem to have premature CAD with >50X
increase in MI in SLE women 35-44 years, and the risk of cardiovascular events being 8-9 X
increased in middle age SLE women [44-45]. We have also reported an increased risk of
myocardial infarction in premenopausal women with SLE [46]. Thus, myocardial infarctions
occur in patients with SLE at younger age than the general population, and using traditional
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risk factors alone is inadequate for developing prevention and treatment programs in asymp‐
tomatic SLE patients [42, 44].
2.4. Cerebrovascular disease
Cerebrovascular disease is increased in SLE with an increased risk of stroke reported to be
1.67, 3.2 and 7.9 X the general population [44, 47-48]. Age and hypertension are associated with
progression of carotid intima media thickness and carotid artery plaque in SLE [43]. Male lupus
patients tend to have a higher prevalence of strokes than females [49]. Antiphospholipid
antibodies are established risk factors for ischemic stroke in lupus [50] and can increase
cerebrovascular atherosclerotic disease [51].
3. Pathogenesis and mechanisms of hypercoagulability
3.1. Chronic inflammation
Chronic Inflammation, which occurs in SLE, contributes to the development of thrombosis
and accelerated atherosclerosis [52]. Inflammation and infections are known epidemiologic
risk factors for venous thrombosis [53]. Inflammation can cause an acquired thrombophilia
and subsequent thrombosis [54]. Inflammation activates the procoagulant arm of the coagu‐
lation system and inhibits anticoagulation and fibrinolysis [55].There is an association of lupus
disease activity (i.e., inflammation) and elevated erythrocyte sedimentation rate and/or C-
reactive protein levels with vascular thrombosis. [5, 6, 56-57]. In fact, complement activation
which occurs in lupus can promote thrombosis by activating the coagulation cascade at
multiple levels [58]. It is well established that venous thrombosis can occur with elevated levels
of procoagulant factors 2, 8, 9 and 10, as well as with decreased levels of anticoagulant factors
(antithrombin 3, protein S and protein S [54]. Coagulation factors that increase with inflam‐
mation include Von Willebrand factor, fibrinogen, Factor VII, and Factor VIII. Increases in high
sensitivity C –reactive protein (HSCRP), fibrinogen and factor VIII are in seen in lupus
anticoagulant-related thrombosis [59]. Additionally, fibrinogen increases with time in SLE
patients which may partially explain the increased risk of thrombosis with increasing years of
lupus disease [11, 60]. Lupus disease activity is associated with elevated procoagulant markers
thrombin-anti thrombin complexes, prothrombin fragment 1+2, and soluble thrombomodulin,
suggesting inflammatory mediated hypercoagulability [61]. Inflammatory cytokines promote
endothelial damage, plaque formation and vascular smooth muscle hypertrophy [62]. Pro-
inflammatory cytokines which activate endothelial and vascular smooth muscle cells include
interleukin 1 (IL-1), interleukin 6 (IL-6), tumor necrosis factor (TNF) and vascular endothelial
growth factor (VEGF), all of which are increased in active lupus, particularly lupus nephritis
[62]. CD 40 ligand is increased in lymphocytes in SLE patients and CD40/CD40 ligand
interactions can cause plaque rupture [62]. Other pro-inflammatory effects which promote
atherosclerosis include chemokines and adhesion molecules. Inflammation induces thrombo‐
sis via endothelial cell dysfunction, tissue factor mediated activation of coagulation, platelet
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activation, impaired function of anticoagulants and suppressed fibrinolytic activity [55]. These
effects all play a role in venous thrombosis in lupus.
3.2. Hypercoagulability
Multiple mechanisms contribute to hypercoagulability in SLE and thrombosis is due to
multiple hits to the clotting system (the multiple-hit theory). It has been shown that elevations
of procoagulant factors in combination have an additive effect on thrombosis [63]. In lupus,
this includes lupus-specific and non- specific thrombogenic factors. As discussed in the
previous paragraph, inflammation can cause elevations of non- lupus related procoagulant
factors. Other factors contributing to hypercoagulability in SLE includes hyperhomocysteine‐
mia [16, 64-66], and elevated plasminogen activator inhibitor-1 ( PAI-1) which decreases
fibrinolytic activity [16, 55], as well as deficiencies of anticoagulant factors such as protein C,
protein S and tissue plasminogen activator (tPA)which activates the fibrinolytic system [17,
55]. Lupus-specific procoagulant factors include antiphospholipid antibodies. Other lupus-
specific factors include antibodies to factor XII [67], prothrombin [68], and annexin V [69-71].
Antiphospholipid antibodies encompass anticardiolipin antibodies, lupus anticoagulant
(LAC), anti- β-2 glycoprotein-1 antibodies and false positive rapid plasma reagin (RPR) tests.
These antibodies are prevalent in SLE and are pathogenically involved in the thromboses,
accelerated atherosclerosis and fetal demise seen in this population. The prevalence of
antiphospholipid antibodies are common in SLE with anticardiolipin antibodies occurring in
17-86% (vs.1-6% in the general population), and LAC noted in 15-30% (vs. 1-4% in the general
population) [72]. Antiphospholipid antibodies cause vascular thrombosis and fetal loss in SLE
[6, 72-76]. The LAC has a much stronger association with venous thrombosis than anticardio‐
lipin antibodies where the thrombosis risk is directly related to increasing titers of these
antibodies, particularly IGG anticardiolipin antibody titers of medium to high titer [5, 72,
77-78]. Low titers or transient presence of these antibodies generally do not cause thrombosis
[72, 77]. These antibodies bind to phospholipids and protein epitopes found in cardiolipin,
annexin V, prothrombin and β-2 glycoprotein-1 [24]. The antiphospholipid antibodies that
recognize epitopes on β-2 glycoprotein-1 also bind serine proteases involved in hemostasis
and fibrinolysis and hence promote thrombosis [79].
The prothrombotic effect of these antibodies occur via multiple mechanisms including platelet
activation, endothelial cell activation with resultant up regulation of adhesion molecules and
production of thromboxane A2, and stimulation of monocytes to make tissue factor, all of
which promote clotting and vasoconstriction [80-81]. Tissue factor activates the extrinsic
coagulation system while tissue plasminogen activator (tPA) activates fibrinolysis. Tissue
factor pathway inhibitor activity is reduced in SLE and this is associated with increased levels
of tissue factor and subsequent hypercoagulability [82]. Antiphospholipid antibodies bind to
components of the coagulation cascade and activate the coagulation system leading to a
procoagulant state along with decreased fibrinolysis via reducing activity of tPA [79-81].
Thrombosis and fetal loss in SLE share the same pathogenic pathways, and the mechanisms
by which antiphospholipid antibodies cause fetal loss and thrombosis are complex and varied.
They include target antigens in the coagulation, endothelial and immune systems summarized
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by Tripodi, et al, as follows [83]: 1.) inhibiting the protein C axis (targets- protein C, protein S,
thrombomodulin, activated protein C ((APC) resistance, endothelial protein C receptor, 2.)
increasing thrombin generation (targets- prothrombin, microparticles, tissue factor pathway
inhibitor, protein Z, Factor XI, Factor XII, heparin cofactor II), 3.), disruption of the protective
shield (target-annexin A5), 4.), decreasing fibrinolysis (targets-tPA, Annexin A2, β-2 glyco‐
protein-1 cleavage), 5.), altering complement levels (targets-C3, C5a, membrane attack
complex, 6.) increasing platelet adhesion (target- Von Willebrand factor) and activation
(targets-low density lipoprotein receptor 8, glycoprotein 1b, platelet factor 4, thromboxane A2,
7.) activation of endothelial cells (targets-Toll like receptor 4, tissue factor, prostacyclin, nitric
oxide), 8.) activation of monocytes (target-tissue factor), 9.) activation of neutrophils (target-
tissue factor), 10.) trophoblast activation (target-growth factor binding), 11.) angiogenesis
(target- vascular endothelial growth factor, basic fibroblast growth factor), and 12.) increased
atherosclerosis ( target-oxidized LDL) [83-84]. In fact, β-2 glycoprotein-1 binds to oxidized LDL
to form atherogenic complexes as discussed above. These complexes have been detected in
patients with autoimmune disease and promote macrophage uptake and subsequent athero‐
sclerosis [85].
4. Laboratory diagnosis
Laboratory diagnosis of hypercoagulability in lupus is complex and depends on where the
patient is in the disease process. In general, more than basic tests are needed to cover the full
range of possibly disrupted clotting mechanisms and this includes testing for lupus specific
antiphospholipid antibodies and other hemostatic markers of coagulation. The lupus-specific
antibodies include lupus anticoagulant, anticardiolipin antibodies, and anti β-2 glycoprotein-1
antibodies. These antiphospholipid antibodies are a heterogeneous group of antibodies
identified by various laboratory tests all of which have some problems with standardization,
specificity, interpretation and quality control [86-89]. The target antigens for these antibodies
include prothrombin, negatively charged phospholipids (such as phosphatidic acid, phos‐
phatidylinositol and phophatidyl serine), protein C, protein S, Annexin V, β-2 glycoprotein-1,
thrombomodulin, factor XII, platelet adhesive receptor glycoprotein GP 1b ( which binds Von
Willebrand factor) and other factors mentioned above [81, 86-90]. Anticardiolipin antibodies
are directed against a protein known as β-2 glycoprotein-1, which binds anionic phospholipids
[86-87]. Lupus anticoagulants encompass a heterogeneous group of antibodies that bind
negatively charged phospholipids. The assay for LAC is a functional assay which measures
the activity of these antibodies [84]. Anticardiolipin antibodies bind directly to cardiolipin as
well as β-2 glycoprotein-1 bound to cardiolipin, and are generally detected by enzyme-linked
immunosorbent assay or ELISA [69]. A subgroup of these anticardiolipin antibodies bind β-2
glycoprotein-1, and it is these anticardiolipin antibodies that are pathogenic for thrombosis.
β-2 glycoprotein-1 is a glycoprotein found on many cells including endothelial cells, astrocytes,
neurons, extravillous cytotrophoblasts, and syncytiotrophoblast cells of the placenta [84]. β-2
glycoprotein-1 has five domains of which domain V binds anionic phospholipids. Antibodies
to domain I seem to be the most important domain related to thrombosis [84, 87]. The anti β-2
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glycoprotein-1 antibodies are considered a “cofactor” for anticardiolipin antibody activity but
are essentially a more specific assay for evaluation of clinically relevant prothrombotic
antiphospholipid antibodies [87].
Detection of these antiphospholipid antibodies by current testing is problematic due to
variable performance in different laboratories as well as difficulty of standardization [83,
86-87]. The recommended method for detecting lupus anticoagulant is a functional assay and
involves a 3 step process: 1) Screening via dilute Russel viper venom time or dRVVT and
activated partial thromboplastin time or APTT, and if results are above normal (i.e., prolonged
dRVVT or APTT) proceed to 2.) Mixing 1:1 of patient: pooled normal plasma and repeat testing.
If results show that the clotting time (dRVVT and APPT) is still prolonged (i.e., not corrected),
then proceed to 3.) Confirmatory step, which is to repeat testing with excess phospholipids.
LAC is present if the confirmatory step shows correction of the clotting time since the LAC
will bind the excess phospholipids and not the coagulation factors [83]. Anticardiolipin
antibodies and anti β-2 glycoprotein-1 antibodies are both measured by ELISA. For anticar‐
diolipin antibodies, there are specific protocols and guidelines for performing this test with
some disagreement about positivity for cut off values at the lower titers [86-87, 91]. The anti
β-2 glycoprotein-1 antibody tests are also done by ELISA but are more specific than the
anticardiolipin antibody ELISA test, due to having a well-defined antigen (β-2 glycoprotein-1)
for this assay, and is more consistent between different laboratories. [86-87]. It is currently
recommended that all three assays be done for evaluation antiphospholipid antibodies in SLE
and patients classified by number and type of tests positive, with the highest risk for throm‐
bosis being in those with positive for all three tests and particularly with the immunoglobulin
G or IgG isotype [83]. Much work still needs to be done to improve standardization, validity
and consistency of test positivity between laboratories.
Along with the antiphospholipid antibodies discussed above which must be measured in
patients with thrombosis or fetal loss in lupus patients with thrombosis or fetal loss, other
hemostatic markers should be measured to better assess coagulation risk in SLE, i.e., a
coagulation risk laboratory profile. This includes a broad panel of testing to include fibrinogen,
factor VII, factor VIII, tPA, PAI-1, plasminogen activity, Von Willebrand factor activity and
antigen, protein S activity, protein C activity homocysteine, and high sensitivity C-reactive
protein or HSCRP [16]. It is also important to remember that estrogens and pregnancy can
induce protein S deficiency and this may compound pregnancy and hormonal therapy
management in lupus. Homocysteine has been associated with thrombosis in SLE, and should
be measured in lupus patients as part of any hypercoagulable work up [16, 92-94]. Interest‐
ingly, rheological evaluation of SLE patients with and without thrombosis showed no
association of blood viscosity and erythrocyte aggregation with thrombosis [95].
Congenital coagulation factors have been studied in in a limited fashion in SLE. The MTHFR
677 C>T polymorphism is associated with elevated homocysteine. This polymorphism was
found to be homozygous form in 16.7% and heterozygous form in 83.3% of SLE patients tested
and the homozygous form was increased in SLE patients vs. controls [57]. On the other hand,
Factor V Leiden and Prothrombin G20210AS gene polymorphisms were not increased in SLE
patients with thrombosis [64, 94]. These 2 gene polymorphisms are generally seen in Northern
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European Caucasian populations so it is not surprising that SLE populations, being more
predominantly African American, would not show any increase of these gene types. The
PROFILE cohort study by Kaiser, et al, assessed 33 single nucleotide polymorphisms (SNPs)
in 1,361 predominantly Caucasian SLE patients and found that genetic risk factors for throm‐
bosis in this cohort differed across ethnic groups, and there was an association of venous
thrombosis and SNPs for these genes in whites for Factor V Leiden (OR=2.69, p=0.002), for
MTHFR (OR=1.51, p=0.01), and for fibrinogen gamma (OR=1.49, p=0.02) [96]. Evaluation of
functional polymorphisms of the coagulation Factor II gene, which is associated with elevated
levels and activity of prothrombin and thrombosis, showed an association of one particular
polymorphism (rs313516 G allele) with SLE susceptibility in African Americans and Caucasi‐
ans [97]. Micro-RNAs are non-coding RNAs which function to control gene regulation post
transcription by regulating mRNA translation or stability. One study assessing micro-RNAs
in SLE showed that specific micro-RNAs resulted in increased tissue factor production and
increased procoagulant activity [98]. There is limited data on PAI-1 promoter 4G/5G poly‐
morphisms in SLE. Increased PAI-1 activity is associated with reduced endogenous fibrinolytic
activity and is a risk factor for thrombosis. The 4G/4G genotype for PAI-1 promoter has the
highest levels of PAI-1 activity and hence the highest risk for thrombosis. SLE patients with
the4G/4G genotype were found to have increased carotid atherosclerosis [99]. In addition, SLE
patients with PAI-1 4G/4G homozygosity were at increased risk for glomerular microthrombi
[100]. An additional risk factor for the development of arterial thrombosis in antiphospholipid
antibody syndrome is the presence of the 4G allele of the 4G/5G polymorphism of the PAI-1
gene [101].
5. Platelet function in SLE
Although platelet hyperfunction plays an important role in thrombosis in SLE, it has not been
well studied in this population. There is some evidence that platelet activation occurs in SLE
and is associated with thrombosis [102-105]. Platelet hyperfunction and platelet activation can
be induced by inflammation or antiphospholipid antibodies [106-108]. Antiphospholipid
antibodies have been shown to bind to β-2 glycoprotein-1 -phospholipid complexes on
activated platelet membranes. Sticky platelet syndrome or hyperfunctioning platelets is a well
described autosomal dominant disorder associated with arterial and venous thrombosis and
characterized by hyperaggregable platelets in response to adenosine diphosphate (ADP),
epinephrine or both [109-111]. Hyperaggregable platelets have been described in other
conditions including diabetes, unstable angina, atrial fibrillation, thrombotic strokes, migraine
headaches, retinal artery occlusions, pre-eclampsia, arterial thromboembolism, nephrotic
syndrome and patients in intensive care units [109-111]. This suggests that platelet aggregation
is a response to stress or epinephrine [109-111]. In women with recurrent miscarriages, sticky
platelet syndrome was found in 21% [112]. Enhanced platelet aggregation was noted in non-
lupus patients with venous thromboembolism [113]. It is logical to assume that SLE patients
would have activated platelets and platelet hyperfunction due to stress, inflammation and
antiphospholipid antibody mediated activation. Few studies have assessed platelet function
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in SLE. Platelet activation markers CD 62 and CD 63 are increased in patients with primary
antiphospholipid antibody syndrome, suggesting platelet activation plays an important role
in thrombosis mediated by antiphospholipid antibodies [114]. In vitro platelet activation
measured by flow cytometry using anti CD 62 was augmented by the presence of lupus plasma
samples containing anticardiolipin antibodies and LAC [115]. Persistent activation of platelets
(measured by platelet induced extracellular phosphorylation of plasma proteins) was seen in
lupus patients, particularly those with thrombosis but not in non-SLE patients with DVT [116].
Our study (Dhar, et al) showed that 70% of SLE patients who had a hypercoaguable state had
hyperfunctioning platelets measured by a functional assay [16].
Platelet hypofunction can also occur in SLE and has also not been well studied. Platelet
hypofunction is usually the result of platelet dense granule deficiency and can result in
bleeding and bruising disorders. Prolonged bleeding times suggesting platelet hypofunction
have been described lupus patients who had LAC [117]. Our study (Dhar, et al) showed that
the patients who had bleeding problems had platelet dense granule deficiency as measured
by electron microscopy [16].
6. Approach to patients: Work up and thrombophilia management
6.1. High risk clinical scenarios
Selecting SLE patients for a coagulation assessment is well established for those with a
thrombosis or fetal loss but is not well defined for those who are at risk but have not yet had
an event. Thus, patients who have had an event should clearly be selected for a coagulation
work up. The guidelines for this are the Sydney Clinical Criteria for antiphospholipid antibody
syndrome [118]. This includes any 1.) vascular ( arterial, venous or small vessel) thrombosis
except for superficial thrombosis, 2.) Pregnancy morbidity (one or more unexplained deaths
of a morphologically normal fetus at or beyond 10 weeks of gestation, one or more premature
births of a morphologically normal neonate at or before 34 weeks gestation due to severe pre-
eclampsia, eclampsia or severe placental insufficiency, or three or more unexplained consec‐
utive spontaneous abortions before the 10th week of gestation excluding anatomic or hormonal
abnormalities or maternal/paternal chromosomal causes [118]. However, medical manage‐
ment should advance towards prevention of thrombosis and adverse fetal outcomes and one
should evaluate high risk clinical settings as reason enough for a thrombophilic risk assess‐
ment. These would include pregnancy, pre-estrogen hormone therapy, pre-tamoxifen therapy,
pre-organ transplant, pre- vascular procedure (such as coronary artery stenting), pulmonary
hypertension, nephrotic syndrome, and chronic inflammatory setting, etc. In other words, one
should assess the risk of thrombosis in the clinical situation and assess the multiple hits on that
background. If the clinical setting is high risk for thrombophilia, one should do the coagulation
profile discussed above along with genetics and platelet function studies. Then once this
information is obtained, one should assess the number and degree of procoagulant hits and
determines a treatment plan. This allows fine tuning of treatment while minimizing bleeding
risk. Treatment strategies should be tailored to minimize bleeding complications, reduce
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recurrence of thrombosis, reduce intrauterine fetal demise, and simplify monitoring. Another
complicating issue for thrombophilia management is that SLE patients frequently have mixed
disorders with both prothrombotic and bleeding tendencies. Thus, when ordering a laboratory
work up, an extensive battery of tests is needed to most accurately define the coagulation
status. Unfortunately, since these factor abnormalities are independent of each other for the
most part, there is no way to truncate the testing to an algorithm. However, as much infor‐
mation as possible should be obtained to determine the procoagulant and anticoagulant factors
that would increase the risk for thrombosis and decide on optimal treatment.
6.2. Thromboprophylaxis for hypercoagulable states
For those SLE patients with hypercoagulability who have not had a thrombosis, treatment
options for hypercoagulability in lupus consist of thromboprophylaxis for acute high risk
situations, chronic prophylaxis for thrombosis prevention, and full dose anticoagulation
therapy. Thromboprophylaxis for patients without any history of thrombosis and presence of
antiphospholipid antibodies is controversial. However, evaluating thrombosis risk by
assessing the multiple hits with a full thrombophilia profile would provide more support for
deciding on intensity and type of thromboprophylactic treatment. High risk settings for which
acute/short term thromboprophylaxis is indicated for antiphospholipid antibody positive
patients would include surgery, ovarian stimulation or other short term hormonal therapy,
pregnancy, vascular procedures, lupus flares, infections, and prolonged immobilization [119].
In pregnant SLE patients positive for lupus anticoagulant, it is recommended that low dose
molecular weight or unfractionated heparin be used during pregnancy since neiher cross the
placenta [19]. It is not recommended to treat thrombophilia in pregnant SLE patients who are
positive for anti cardiolipin antibodies or lupus anticoagulant with corticosteroids since only
anticoagulation has been shown to be of proven benefit in preventing thrombosis and fetal
loss [19]. Corticosteroids have no benefit in preventing thrombotic complications in this setting
and should only be used if any active lupus disease is present [19]. In addition, there is no role
for prophylactic corticosteroids in patients who have no active lupus disease. Corticosteroids
are relatively safe to use during pregnancy from a fetal standpoint, since the placenta metab‐
olizes 90 % of non-flourinated corticosteroids. However, corticosteroids increase maternal
complications such as hypertension and gestational diabetes [19]. Appropriate settings for
chronic thromboprophylaxis would include those patients with persistent medium to high
titers of anticardiolipin antibodies, those with triple antiphospholipid antibody positivity
(+LAC, +anticardiolipin antibody, and +anti β-2 glycoprotein-1 antibody), and those with
multiple hits on a background of high risk clinical settings such as, long term hormonal
therapy, nephrotic syndrome, cardiovascular disease, and history of obstetric antiphospholi‐
pid antibody related events [119]. Both platelet function and the balance of procoagulant and
anticoagulant factors should be assessed. Low dose aspirin therapy for prophylaxis is recom‐
mended by the Task Force at the 13th International congress on Antiphospholipid Antibodies
for these aforementioned situations along with lifestyle changes and is commonly accepted as
standard treatment by many [120-121]. In SLE patients with antiphospholipid antibodies, the
task force recommends both low dose aspirin and hydroxychloroquine [120]. In pregnant SLE
patients with antiphospholipid antibodies only and no previous history of pregnancy loss, low
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dose aspirin is recommended [122]. If platelet hyperfunction is present, low dose aspirin is
indicated. If hyperhomocysteinemia is present, folic acid and B complex should be used to
lower homocysteine levels to below 10 µmoles/liter. However, if other high risk situations are
identified in which thrombosis is likely, such as very low protein S activity, then anticoagula‐
tion with warfarin or low molecular weight heparin is indicated.
6.3. Treatment of hypercoagulable states with prior vascular thrombosis
For those SLE patients with antiphospholipid antibodies and hypercoagulablity who have had
an arterial or venous thrombosis full dose anticoagulation is recommended with unfractio‐
nated or low molecular weight heparin (e.g., enoxaparin, dalteparin), fondaparinux (a
synthetic of the minimal anti thrombin binding sequence of heparin), vitamin K antagonists
(e.g., warfarin), direct thrombin inhibitors (e.g., dabigatran), or direct factor Xa inhibitors (e.g.,
rivaroxaban) [83, 123]. For acute arterial or venous thrombosis, treatment consists of an initial
course of unfractionated or low molecular weight heparin followed by indefinite long term
treatment with warfarin to keep the international normalized ration or INR between 2.0-3.0,
heparin- type drugs, or more recently, one of the newer thrombin or factor Xa inhibitors. For
arterial thrombosis (stroke, myocardial infarction), addition of antiplatelet agents (low dose
aspirin, clopidogrel 75 mg) may be helpful, particularly if platelet hyperfunction is present [16,
83]. The disadvantage of using warfarin is the difficulty of maintaining the correct therapeutic
INR range and frequency of INR testing that must be done, which is inconvenient to the patient.
The disadvantage of the heparin- type drugs is that the patient must administer self-injections
daily. The heparin- type drugs do have one advantage in that coagulation lab monitoring is
unnecessary. The newer thrombin or factor Xa inhibitor drugs have the dual advantage of
being an oral medication and not requiring laboratory anticoagulation monitoring. For
catastrophic antiphospholipid antibody syndrome, which has a high mortality rate, treatment
with plasma exchange, high dose corticosteroids, intavenous immunoglobulins and anticoa‐
gulation is recommended [124].
6.4. Pregnancy
SLE pregnancies should be considered high risk and must be managed in a multidisciplinary
setting to address three problem areas: hypertensive pregnancy complications, lupus disease
activity and thrombophilia [19]. Pregnancy is a hypercoagulable state which is worsened by
the inflammation of active lupus disease. Pregnancy outcomes are worse with active lupus,
particularly nephritis and active central nervous system (CNS) disease. Thus, it is recom‐
mended that patients with SLE have planned pregnancies and not attempt conception until
the disease has been in remission for the preceeding 6 months [19]. Pregnancies that occur
during active lupus or in patients with a history of severe major organ involvement such as
nephritis or CNS disease are higher risk for poor fetal outcomes and maternal complication
[19].Patients with mild disease generally have good pregnancy outcomes. For those pregnant
SLE patients with no prior pregnancy loss or previous vascular thrombosis who have anti
phospholipid antibodies, it is recommended that prophylaxis with low dose aspirin be used
[125]. However if there are multiple hits such as triple antiphospholipid antibody positivity,
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low dose aspirin along with prophylactic doses of unfractionated or low molecular weight
heparin be used [125-126]. Pregnancy- induced protein S deficiency can occur in these patients
and when present should be treated with full dose anticoagulation with of unfractionated or
low molecular weight heparin to prevent pregnancy loss. For pregnant SLE patients with
antiphospholipid antibodies, other hypercoagulability factors, and a previous pregnancy loss
or vascular thrombosis, treatment with full dose of unfractionated or low molecular weight
heparin along with dose aspirin is recommended [127-128]. Generally anticoagulation is
interrupted briefly during the delivery period and resumed and continued post- partum until
the protein S levels return to normal and the other coagulation parameters correct. For
antiphospholipid antibody persistence post-partum, continued treatment with daily aspirin
is often used. Although these treatments for pregnant SLE patients are generally accepted,
there is a lack of definitive data from clinical trials to support these accepted regimens [83].
6.5. Adjuvant treatments
Other adjuvant treatments summarized by Mehudi [81] for antiphosphoipid antibodies in SLE
include: 1.) statins (which decrease antiphospholipid antibody mediated thrombosis and
inflammation, 2.)Ritxuamib (which depletes CD 20 B lymphocyte cells involved in antiphos‐
pholipid antibodyl mediated disease), 3.) Hydroxychloroquine (which inhibit platelet aggre‐
gation of antiphospholipid- activated platelets by binding to GPIIbIIIa and by binding β-2
glycoprotein-1 or to target cells), 4.) Specific GPIIbIIIa inhibitors (e.g,abciximb) which bind
and inactivate GPiia IIIb which is upregulated on antiphospholipid antibody activated
platelets, 5.) inhibitors of tissue factor up regulation seen in antiphopholipid antibody
activated endothelial cells (e.g., ACE inhibitors), 6.) anti TNF therapy to block high TNF levels
seen in antiphospholipid antibody positive patients, 7.) blockage of receptors for β-2 glyco‐
protein-1 or antiphospholipid antibodies on target cells [81].
7. Conclusion
It is clear that thrombophilia assessment and management is complex in SLE. The balance of
procoagulant factors, anticoagulant factors and platelet function determine the overall
hypercoagulability risk. Simply testing for antiphospholipid antibodies alone is inadequate
for determining thrombophilia status and risk in SLE. Extended coagulation profile testing
along with genetic evaluation of procoagulant markers and measurements of platelet function
provide more clear and precise information to develop a thrombotic or fetal loss risk assess‐
ment in SLE. This allows for fine tuning of prophylactic or full dose anticoagulation treatment
and may help determine intensity and length of treatment. The overall benefit of this extended
testing is to improve selection of patients to treat, improve management of anticoagulation
therapy, reduce re-thrombosis and fetal loss risk, and minimize treatment complications.
Further research is needed to better elucidate the multiple mechanisms behind hypercoagul‐
ability in lupus with thrombotic risk stratification and subsequent development of more
definitive treatment recommendations.
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